AbbVie Reported GAAP Earnings & Adj Non-GAAP Earnings For Q4 Expected To Include Acquired LPR&D And Milestones Expense Of $282M On A Pre-Tax Basis
Portfolio Pulse from Benzinga Newsdesk
AbbVie has reported in an SEC filing that its GAAP and adjusted non-GAAP earnings for Q4 will include an acquired LPR&D and milestones expense of $282 million on a pre-tax basis.
January 05, 2024 | 9:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie's Q4 earnings will be impacted by an additional expense of $282 million due to acquired LPR&D and milestones, which could affect both GAAP and non-GAAP earnings.
The additional expense of $282 million is significant and directly affects AbbVie's earnings for Q4. This could lead to a negative perception among investors regarding the company's profitability and financial performance, potentially causing a short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100